Literature DB >> 6355314

Antimicrobial therapy of chancroid: effectiveness of erythromycin.

F A Plummer, L J D'Costa, H Nsanze, I W Maclean, P Karasira, P Piot, M V Fast, A R Ronald.   

Abstract

The emergence of Haemophilus ducreyi resistant to multiple antibiotics has limited the effectiveness of sulfonamides and tetracycline for the therapy of chancroid. A randomized, double-blind study compared 10-day courses of erythromycin base (500 mg) and rosaramicin (250 mg) each given four times daily for the treatment of men with chancroid in Nairobi, Kenya. Of 99 evaluable patients, 84 were positive for H ducreyi. H ducreyi-positive genital ulcers in men treated with either drug resolved with mean +/- SD healing times of 10.8 +/- 5.1 days for erythromycin and 10.7 +/- 5.5 for rosaramicin. There were no clinical or bacteriologic failures with either agent. Fifteen men with H ducreyi-negative genital ulcers for whom no other etiology could be determined also responded rapidly to treatment with either agent. Both erythromycin and rosaramicin are highly effective in the treatment of chancroid.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6355314     DOI: 10.1093/infdis/148.4.726

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  8 in total

Review 1.  Antimicrobial susceptibility of Haemophilus ducreyi.

Authors:  Y Dangor; R C Ballard; S D Miller; H J Koornhof
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

Review 2.  Treatment of chancroid.

Authors:  Y Dangor; R C Ballard; S D Miller; H J Koornhof
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

3.  Clinical evaluation of rosoxacin for the treatment of chancroid.

Authors:  D A Haase; J O Ndinya-Achola; R A Nash; L J D'Costa; D Hazlett; S Lubwama; H Nsanze; A R Ronald
Journal:  Antimicrob Agents Chemother       Date:  1986-07       Impact factor: 5.191

4.  In vitro activities of U-63366, a spectinomycin analog; roxithromycin (RU 28965), a new macrolide antibiotic; and five quinolone derivatives against Haemophilus ducreyi.

Authors:  M J Sanson-Le Pors; I M Casin; M C Thebault; G Arlet; Y Perol
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191

5.  Single-dose ceftriaxone for chancroid.

Authors:  M I Bowmer; H Nsanze; L J D'Costa; J Dylewski; L Fransen; P Piot; A R Ronald
Journal:  Antimicrob Agents Chemother       Date:  1987-01       Impact factor: 5.191

6.  Antimicrobial susceptibility and characterization of outer membrane proteins of Haemophilus ducreyi isolated in Thailand.

Authors:  D N Taylor; P Echeverria; S Hanchalay; C Pitarangsi; L Slootmans; P Piot
Journal:  J Clin Microbiol       Date:  1985-03       Impact factor: 5.948

7.  Evaluation of 500- and 1,000-mg doses of ciprofloxacin for the treatment of chancroid.

Authors:  L Bodhidatta; D N Taylor; A Chitwarakorn; K Kuvanont; P Echeverria
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

Review 8.  Chancroid and Haemophilus ducreyi.

Authors:  S A Morse
Journal:  Clin Microbiol Rev       Date:  1989-04       Impact factor: 26.132

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.